• MeiraGTx struck an up to USD 400 million financing with Oberland Capital to fund development, launch preparation for late-stage gene therapies.
• Structure includes up to USD 375 million in non-dilutive royalty funding, up to USD 25 million in equity.
• Initial funding totals USD 135 million, including USD 125 million for low single-digit capped royalties, USD 10 million equity.
• Additional tranches include USD 50 million tied to AAV2-hAQP1 Phase 2 AQUAx2 data in 2027, USD 50 million tied to bota-vec approval in 2027.
• Oberland to receive capped low single-digit royalties on net sales of AAV2-hAQP1, bota-vec, AAV-AIPL1 following regulatory approvals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MeiraGTx Holdings plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-080949), on July 07, 2026, and is solely responsible for the information contained therein.